Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2014
Q3
$10K Sell
683
-100
-13% -$1.98K ﹤0.01% 8890
2014
Q2
$20K Sell
783
-1,534
-66% -$35K ﹤0.01% 8121
2014
Q1
$49K Sell
2,317
-450
-16% -$16K ﹤0.01% 6874
2013
Q4
$104K Buy
2,767
+2,717
+5,434% +$49.5K ﹤0.01% 6033
2013
Q3
$1K Sell
50
-283
-85% -$4.17K ﹤0.01% 10269
2013
Q2
$4K Buy
+333
New +$4.91K ﹤0.01% 9548

Other funds holding CYTR

UBS's CYTR Position: Q3 2014 in Review

UBS increased its CytRx Corp (CYTR) stake by 30% in Q3 2014, buying an estimated $1.17K and bringing the position to 258 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #9731.

UBS first reported a position in CYTR in Q2 2013 and has held it in 6 quarters since. The position peaked at $460K in Q1 2014. 69 funds tracked by Wall St. Rank hold CYTR as of Q3 2014.

  • UBS held 258 shares of CytRx Corp worth $4K as of Q3 2014.
  • UBS bought 59 CytRx Corp shares in Q3 2014, an estimated $1.17K.
  • CytRx Corp made up ﹤0.01% of UBS's portfolio in Q3 2014, its #9731 holding.
  • UBS first reported a position in CytRx Corp in Q2 2013 and has held it in 6 quarters since.
  • UBS's CytRx Corp position peaked at $460K in Q1 2014.
  • 69 funds tracked by Wall St. Rank held CytRx Corp as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.